Efficacy of B-vitamins and vitamin D therapy in improving depressive and anxiety disorders: a systematic review of randomized controlled trials.

What It Covers

Researchers studied Vitamin D, K2, Magnesium and Zinc and Cyanocobalamin (Vitamin B12) in this systematic review publication.

The researchers also aimed to gather the evidence supporting the recommendations for supplementation in clinical practice.

In addition, the RCTs were included if the scales to assess the severity of the symptoms were standardized rating scales in psychiatric.

Who the Included Studies Covered

By PubMed's age tags, the people studied were teenagers, both men and women.

Performed between March 2020 and September 2021, the main inclusion criteria were randomized controlled trials (RCTs), with patients ≥ 18 years old, both sexes, fulfilling target diagnoses of major depressive disorder (MDD), generalized anxiety disorder (GAD), or mild to severe depressive and anxiety symptoms.

Trials that reported diagnoses of schizophrenia, perinatal depression, bipolar depression, sleep disorders, eating disorders, cancer, and multiple sclerosis in association with any of the mentioned diagnoses were excluded.

What Was Measured

PubMed files the paper under topics including Vitamin B Complex, Randomized Controlled Trials as Topic, Anxiety Disorders, Vitamin D and Major Depressive Disorder.

The authors tagged it with the keywords B vitamins, Homocysteine, L-methylfolate, generalized anxiety disorder, thiamine and vitamin B12.

What This Means in Plain Language

This is a systematic review of Vitamin D, K2, Magnesium and Zinc and Cyanocobalamin (Vitamin B12).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Nutritional neuroscience), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Cyanocobalamin (Vitamin B12) compound page, all human trials.